跳至主要内容
临床试验/NCT01294839
NCT01294839已完成不适用

Right Ventricular Outflow Tract Septal Pacing for Cardiac Dysfunction Prevention Evaluation

Abbott Medical Devices1 个研究点 分布在 1 个国家目标入组 380 人开始时间: 2011年3月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
380
试验地点
1
主要终点
Left ventricular ejection fraction (LVEF)

研究概览

简要总结

This is a prospective, randomized, double blinded, multi-center, controlled study to evaluate the clinical impact at 18 months after DDD implantation of alternative pacing site (RVOTs and RVA) and the different conduction path (RVOTs and AV node) on cardiac dysfunction prevention.

详细描述

Ventricular pacing is unavoidable in many patients because of unreliable or absent AV conduction, or permanent AF. In recognition of this need, interest has focused on alternative site(s) ventricular pacing to maximize pumping function. These sites include the RV septum, His bundle, various LV sites, and combination of LV and RV (biventricular [BiV]). The RV outflow tract septum (RVOTs) seems to be the most promising site within the RV.

However, small enrollment and inconsistent experimental methods hinder the interpretation of these studies. Locations of alternative pacing sites were not clearly specified, were largely topographic, and lacked consistent anatomic designation. And what is more, there was no prospective, double-blind randomized, multi-center clinical trial which is design to test whether RVOTs pacing is superior to right ventricular apical pacing in preserving left ventricular systolic function and avoiding adverse left ventricular remodeling in patients with a normal left ventricular ejection fraction, ventricular synchrony and standard indications for pacing (sinus node dysfunction) in China. There was also no prospective, double-blind randomized, multi-center clinical trial which is design to test whether RVOTs pacing is not inferior to AAIR pacing in preserving left ventricular systolic function and avoiding adverse left ventricular remodeling in patients with a normal left ventricular ejection fraction, ventricular synchrony and sinus node dysfunction in the world.

So SJM China will sponsor a prospective, randomized, double blinded, multi-center, controlled study to evaluate the clinical impact at 18 months after DDD implantation of alternative pacing site (RVOTs and RVA) and the different conduction path (RVOTs and AV node) on cardiac dysfunction prevention.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with only sinus-node dysfunction and meet pacing indication
  • Patients with LVEF≥60% and with ventricular synchrony.
  • Patients signed the written informed consent for the study
  • Patients can endure the required follow up

排除标准

  • Patients with atrial fibrillation
  • Patients with atrial-ventricular block
  • Patients with LBBB
  • Patients with significant valvular disease
  • Patients with severe hematopathy or severe renal inadequacy
  • Patients with life expectancy < 1.5 year
  • Patients who are in the period of pregnant or lactation
  • Patients who are younger than 18 years old
  • Patients who are ongoing other devices or agents study

研究组 & 干预措施

RVOTs

Experimental

555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVOTs arm, the RV lead of this group patients will be implanted in right ventricular outflow tract septum,the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.

干预措施: Right ventricular lead location (Device)

AAI

Experimental

555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in AAI arm, the RV lead of this group patients will be implanted in right ventricular apex.

干预措施: Right ventricular lead location (Device)

RVA

Active Comparator

555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVA arm, the RV lead of this group patients will be implanted in right ventricular apex, the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.

干预措施: Right ventricular lead location (Device)

结局指标

主要结局

Left ventricular ejection fraction (LVEF)

时间窗: 18 months

To demonstrate: * Whether RVOTs pacing is superior to right ventricular apical pacing in preserving left ventricular systolic function in patients with a normal left ventricular ejection fraction, ventricular synchrony and standard indications for pacing(sinus node dysfunction) * Whether RVOTs pacing is not inferior to AAI pacing in preserving left ventricular systolic function in patients with a normal left ventricular ejection fraction, ventricular synchrony and sinus node dysfunction.

次要结局

  • left ventricular end-systolic volume (LVESV)(18 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验